Salmonelle as Next Generation Probiotics
Creative Biolabs provides scale-up and good manufacturing practice (cGMP) manufacturing of live biotherapeutics for pre-clinical, clinical, and commercial scale. With Ph.D. level scientists and substantial experience and expertise in the development of next-generation probiotics (NGPs), we are dedicated to offering custom cGMP manufacturing of Salmonelle with the best quality and most competitive price.
Features of Salmonella
Belonging to the Enterobactericae family, Salmonella is a group of Gram-negative, facultatively anaerobic, and facultatively intracellular pathogenic bacteria. Currently, based on genome sequence similarity, the genus Salmonella is categorized into two species-S. bongori and S. enterica. S. Typhimurium and S. Typhi are closely related serotypes of S. enterica species. S. Typhimurium infection in humans is restricted to the digestive tract, exception of infants, elderly or immunocompromised individuals in whom it can spread. On the contrary, S. Typhi causes typhoid fever in humans but is not pathogenic to animals. In general, serotypes that lack host specificity, such as S. Typhimurium, are more frequently associated with disease in young rather than in adult animals, suggesting their non-optimal adaptation to the mature immune system.
Fig.1 Targets for engineered live biotherapeutics in the gastrointestinal tract. (Ozdemir, 2018)
Background of Salmonella-mediated Cancer Therapy
Bacterial cancer therapy is a concept more than 100 years old. Since then, a wide range of advancements has been made especially in the advent of microbial engineering, Salmonella Typhimurium being one of the most promising. Recent developments include attenuated profiles of Salmonella for safe delivery. Moreover, Salmonella-mediated cancer therapies are genetic engineering of the bacteria for optimized tumor targeting and anticancer effects. Salmonella-mediated cancer therapy has been paid close attention and many advances have been achieved. For instance, careful design has led to the use of attenuated Salmonella as drug delivery vehicles and tumor-targeting therapeutics with excellent safety and therapeutic efficacy in countless murine tumor models. Besides, Salmonella has the potential for use as an imaging and diagnostic tool that would improve patient prognosis through early awareness. Furthermore, implications for further clinical testing of Salmonella-mediated cancer therapy is under study.
cGMP Manufacturing of Salmonelle at Creative Biolabs
Continued innovative discovery will yield a promising future for the use of Salmonella-mediated cancer therapies in cancer care. Recent advances in synthetic biology and genetic engineering technology allow the design and construction of engineered live biotherapeutics targeting a range of human clinical applications. With Ph.D. level scientists and extensive experience in the design and construction of engineered live biotherapeutics, Creative Biolabs is proficient in the development of engineered Salmonelle and provides scale-up and cGMP manufacturing of Salmonelle products.
Highlights of Our Salmonelle Drug Discovery Services
-
Salmonella typhimurium(attenuated, engineered)
-
Salmonella tyhpi (attenuated, engineered)
-
cGMP Manufacturing
-
Highly professional Ph.D. level scientists
-
Top-rated customer experience
Equipped with world-leading technology and professional scientific staff, Creative Biolabs is pleased to share our extensive expertise in the design, construction, and cGMP manufacturing of engineered Salmonella. We are confident that our technology will meet customer's needs from early research to commercial production. For more detailed information, please feel free to contact us or directly send us an inquiry.
Reference
-
Ozdemir, T.; et al. Synthetic biology and engineered live biotherapeutics: toward increasing system complexity. Cell systems. 2018, 7(1): 5-16.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
